Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Trial crawled date : 2021 - 10 - 27 save search
Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Received IND Approval for Phase 1/1b Clinical Trial of ITK Inhibitor CPI-818 in ChinaCPI-818 clinical trial in China will be conducted by Angel Pharmaceuticals
Published: 2021-10-27 (Crawled : 21:00) - biospace.com/
CRVS | $1.4 -0.71% -0.71% 59K
|
Health Technology
|
| O: -2.45%
H: 5.25%
C: 4.11%
phase 1 china trial approval
Inventiva announces the design of LEGEND, a Phase IIa combination trial with lanifibranor and SGLT2 inhibitor empagliflozin in patients with NASH and type 2 diabetes
Published: 2021-10-27 (Crawled : 20:00) - inventivapharma.com
IVA | $3.35 -2.9% -2.99% 8.5K
|
Health Technology
|
| O: -1.03%
H: 1.25%
C: 0.24%
diabetes nash trial designation
Plus Therapeutics Announces Presentation of ReSPECT-GBM Trial Dosimetery Data at the American Society for Radiation Oncology (ASTRO) 2021 Annual Meeting
Published: 2021-10-27 (Crawled : 18:00) - globenewswire.com
PSTV | $1.67 -1.27% -1.28% 25K
|
Health Technology
|
| O: 1.17%
H: 5.78%
C: 5.2%
presentation trial
Biomica & Rambam Health Care Campus Sign Agreement for Clinical Trial of Biomica's Microbiome-Based Immuno-Oncology Drug
Published: 2021-10-27 (Crawled : 13:15) - biospace.com/
EVGN | $0.7 -13.64% 63K
|
Health Technology
|
| O: 1.15%
H: 1.13%
C: -3.77%
drug trial
Kymera Therapeutics Presents Positive Data Demonstrating Robust IRAK4 Degradation and First Proof-of-Biology with Inhibition of Cytokine Induction from the Single Ascending Dose Portion of KT-474 Phase 1 Trial in Healthy Volunteers
Published: 2021-10-27 (Crawled : 13:15) - biospace.com/
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.91%
H: 0.06%
C: -1.04%
KYMR | $33.965 -3.29% -3.4% 630K
|
Health Technology
|
| O: -0.5%
H: 3.25%
C: 0.66%
phase 1 positive trial
Monopar Announces First Patient Dosed in Phase 1b Trial Evaluating Camsirubicin for the Treatment of Advanced Soft Tissue Sarcoma
Published: 2021-10-27 (Crawled : 13:15) - biospace.com/
MNPR | $0.636 -6.19% -6.6% 33K
|
Health Technology
|
| O: 4.88%
H: 7.64%
C: 3.31%
treatment phase 1 phase 1b trial phase 2b soft tissue
Nurix Therapeutics Announces Initial Data from the First Phase 1a Dose Escalation Trial of NX-2127 in Patients with Relapsed or Refractory B Cell Malignancies
Published: 2021-10-27 (Crawled : 13:00) - biospace.com/
NRIX 3 d | $13.6 -5.82% -6.18% 1M
|
Health Technology
|
| O: 9.5%
H: 15.97%
C: 8.74%
phase 1 trial phase 1b t-cell
Kezar Announces First Patient Dosed in Phase 1 Trial of KZR-261 in Advanced Solid Tumor Malignancies
Published: 2021-10-27 (Crawled : 13:00) - biospace.com/
KZR | $0.7875 -0.01% -0.01% 420K
|
Health Technology
|
| O: 0.83%
H: 0.0%
C: -6.36%
phase 1 trial solid tumors phase 2
Adagene Establishes Collaboration for Clinical Trial of ADG106 in Combination with Nivolumab in Patients with Non-Small Cell Lung Cancer in Singapore
Published: 2021-10-27 (Crawled : 12:15) - biospace.com/
ADAG | $2.63 -0.38% -0.38% 5.4K
|
Manufacturing
| Email alert
Add to watchlist
lung cancer collaboration cancer trial nivolumab
Biohaven Enrolls Phase 1a/1b Clinical Trial of BHV-1100, Lead Asset from its ARM™ (Antibody Recruiting Molecule) Platform, in Combination with NK Cell Therapy for the Treatment of Multiple Myeloma
Published: 2021-10-27 (Crawled : 12:00) - prnewswire.com
BHVN 1 d | $38.99 -7.52% 0.0% 3.4M
|
Health Technology
|
| O: 0.21%
H: 0.1%
C: -3.26%
treatment phase 1 therapy antibody trial phase 1b enroll
Context Therapeutics® and Wisconsin Oncology Network Announce First Patient Dosed in Phase 2 Trial of ONA-XR in Metastatic Breast Cancer
Published: 2021-10-27 (Crawled : 12:00) - globenewswire.com
CNTX | $1.39 -1.42% -1.44% 5.7K
|
Health Technology
|
| O: -4.01%
H: 2.16%
C: -3.45%
phase 2 cancer breast cancer trial ona-xr metastatic breast cancer
Merck Presents New Data from Ongoing Phase 2b Clinical Trial Evaluating Efficacy and Safety of Investigational Islatravir in Combination With Doravirine Through 144 Weeks for HIV-1 Treatment at EACS 2021
Published: 2021-10-27 (Crawled : 12:00) - biospace.com/
MRK | News | $125.78 0.44% 0.0% 8.4M
|
Health Technology
|
| O: 0.71%
H: 0.0%
C: -1.14%
treatment phase 2 ongoing phase 2b trial hiv
Science 37® and 3H Medi Solution Collaborate to Enable Decentralized Clinical Trials in Japan and Accelerate Patient Enrollment
Published: 2021-10-27 (Crawled : 12:00) - globenewswire.com
SNCE | $5.75 0.26% 49K
|
| Email alert
Add to watchlist
clinical trials trials trial enroll
Immunic, Inc. Announces First Psoriasis Patient Enrolled in Ongoing Phase 1 Trial of IMU-935
Published: 2021-10-27 (Crawled : 11:00) - prnewswire.com
IMUX | $1.2 -5.51% -5.83% 360K
|
Health Technology
|
| O: -1.5%
H: 4.23%
C: 2.0%
psoriasis ongoing phase 1 trial phase 2 enroll phase 3
Ocugen, Inc. Announces Submission of Investigational New Drug Application with U.S. FDA to Initiate a Phase 3 Clinical Trial Evaluating COVID-19 Vaccine Candidate COVAXIN™ (BBV152)
Published: 2021-10-27 (Crawled : 11:00) - globenewswire.com
OCGN | News A | $1.315 -0.38% -0.38% 6.5M
|
Health Technology
|
| O: 0.44%
H: 7.18%
C: 4.57%
covid new drug fda application vaccine drug phase 3 trial submission bbv152
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
GBR | $1.42 31.48% 11.27% 990K
|
Energy Minerals
KUKE | $2.88 2.49% 7.64% 360K
|
CXM 4 | $11.34 -0.44% 4.27% 1.7M
|
Information
PVL 4 | $1.47 -0.68% 4.08% 77K
|
Energy Minerals
RNR 4 | $224.74 0.85% 3.52% 310K
|
Finance
PZG | $0.4431 0.48% 2.91% 150K
|
Non-Energy Minerals
SIX | $23.45 -0.55% 0.68% 650K
|
Consumer Services
NEWP | $1.97 0.61% 310K
|
Mining, Quarrying, and Oil and ...
KNSL 4 | $451.81 -0.02% 0.49% 140K
|
Finance
SENS | $0.3992 -4.04% 0.45% 2M
|
Electronic Technology
Your saved searches
Save your searches and get alerts when important news are released.